What question did this study set out to answer?

To investigate whether empagliflozin pretreatment and periprocedural beta-hydroxybutyrate infusion provide cardioprotection against ischemia-reperfusion injury during acute myocardial infarction.

April 1, 2023Circulation Cardiovascular Imaging

Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction

View Full Paper

Ask AI

Bookmark

Why the study?

Does empagliflozin pretreatment or BOHB infusion reduce ischemia reperfusion injury and infarct size during acute myocardial infarction?

Comparison

One-week pretreatment with empagliflozin vs periprocedural intravenous infusion of BOHB

Authors

CSCarlos G. Santos‐GallegoHeart Failure & Transplant JRJuan Antonio Requena-IbáñezMount Sinai Hospital BPBelén PicatosteHospital Universitario Fundación Jiménez Díaz

Discussion

Member takes

Implication

Does not support clinical use in acute MI; hypothesis-generating for empagliflozin and BOHB in animal ischemia-reperfusion models.

Key Points

To investigate whether empagliflozin pretreatment and periprocedural beta-hydroxybutyrate infusion provide cardioprotection against ischemia-reperfusion injury during acute myocardial infarction.
Administered a 1-week pretreatment with the SGLT2 inhibitor empagliflozin prior to acute myocardial ischemia-reperfusion.
Delivered a periprocedural intravenous infusion of beta-hydroxybutyrate (BOHB) during the ischemic period.
Empagliflozin pretreatment reduced myocardial infarction size and microvascular obstruction while increasing myocardial salvage and preserving left ventricular systolic function.
Empagliflozin lowered cardiac apoptosis and oxidative stress levels.
Direct intravenous infusion of BOHB during ischemia independently induced cardioprotection.

Structured PICO

Does empagliflozin pretreatment or BOHB infusion reduce ischemia reperfusion injury and infarct size during acute myocardial infarction?

Population

Acute myocardial infarction (ischemia reperfusion injury) model

Intervention

One-week pretreatment with empagliflozin or periprocedural intravenous infusion of beta-hydroxybutyrate (BOHB)

Outcome

Ischemia reperfusion injury, myocardial infarction size, microvascular obstruction, myocardial salvage, left ventricle systolic function, apoptosis, and oxidative stresssurrogate

Empagliflozin pretreatment and BOHB infusion provide cardioprotection during acute myocardial infarction by reducing infarct size and preserving systolic function, suggesting ketone body availability as a mechanism of SGLT2 inhibitor benefit.

Cite This Study

Santos‐Gallego et al. (2023) studied this question.

synapsesocial.com/papers/69d862c205ee2ba81dbefa29 https://doi.org/10.1161/circimaging.123.015298

View Full Paper

Ask AI

Bookmark

Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider